Active Biotech AB (publ) (0GQU.L)
LSE · SEK
SEK 3.20 (-8.58%) as of
Key statistics
- EPS (TTM)
- -0.2520
- 52-week range
- 3.1950 – 3.1950
- Beta
- 1.39
- Profit margin
- 0.00%
- Volume
- 602.00
About Active Biotech AB (publ)
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
- Headquarters
- Lund, Sweden
- Employees
- 5
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.